Objectives/Hypothesis: To describe the management and outcomes of Fanconi anemia (FA) patients with head and neck squamous cell carcinoma.
INTRODUCTION
Fanconi anemia (FA) is a rare recessive disorder (1-2:100,000 births) 1, 2 caused by mutations in one of at least 19 known genes (FANC[Fanconi anemia complementation group]A/B/C/D1/D2/E/F/G/I/J/L/M/N/O/P/Q/ R/ S/T), 3 with patients having mutations in the same gene forming each of the 19 complementation groups (FA-A to FA-T). The proteins encoded by these genes act together to protect genomic integrity; the mechanism of their function is under intense study in many laboratories. It has been shown that the FA pathway is involved in interstrand crosslink repair, [4] [5] [6] although it clearly responds to conditions of replication stress. 7, 8 Eight of the FA gene products interact in a core complex that localizes to the sites of damage or stalled replication forks. 5 The FANCL component of the core complex monoubiquinates two other FA gene products, FANCD2 and FANCI, 9 ,10 which in turn activate effector pathways including nucleases, translesion polymerases, and homologous recombination machinery. 6, 11, 12 Because of its function in DNA repair, FA belongs to a group of hereditary disorders called caretaker gene diseases, which also include ataxia-telangiectasia, nucleotide excision repair syndromes, Bloom syndrome, hereditary nonpolyposis colorectal cancer, and hereditary breast/ ovarian cancer syndromes. 13 Fanconi anemia is characterized clinically by bone marrow failure that can affect any of the hematopoietic lineages, congenital malformations (short stature, radial ray anomalies, caf e au-lait spots, cardiac and renal anomalies), sensitivity to DNA cross-linking agents, and increased risk of malignancy. 1 The correlation between genotype (the complementation group and the actual mutation) and phenotype is very poorly understood. The severity of the phenotype is determined in part by the patient's specific complementation group and the type of pathogenic genetic variants inherited.
14 Previous studies have established that patients in group FANCC have a more severe FA phenotype, characterized by earlier onset of bone marrow failure and poorer survival compared to groups FANCA and FANCG. 15 Biallelic mutations in BRCA2 and PALB2 results in the most severe phenotype of tumor predisposition. Because of these phenotypic differences among complementation groups, FA is a heterogeneous disorder. Patients may be severely affected with multiple congenital anomalies and severe aplastic anemia, or they may have a mild phenotype, with no major malformations or hematologic abnormalities. 16, 17 Leukemia, specifically acute myeloid leukemia, historically has been the most common cancer in FA patients, but patients are also at a significantly increased risk of developing solid tumors, with a 28% cumulative incidence of solid cancers by the age of 40. 15 In particular, head and neck squamous cell carcinomas (HNSCCs) are significantly more common in FA patients relative to the general population, 18 with some reports calculating a 500 to 700 hundred-fold risk increase. 19 Because hematopoietic stem cell transplantation (HSCT), preleukemia detection, leukemia therapies, and other recent advances have improved the survival of FA patients into adulthood, 20 an increasing number of these patients are developing HNSCCs. One hypothesis of cancer development in FA patients relates to the defects in DNA damage repair and consequent increases in the genomic instability in the epithelial cells of the head and neck region. 21, 22 The standard treatment for HNSCC in the general population incorporates a combination of surgery, radiation, and chemotherapy, depending on the tumor characteristics and clinical stage. Adjuvant radiation and chemotherapy therapy is often recommended to treat patients with higher stage tumors. Definitive radiation with or without chemotherapy is also used to treat certain HNSCCs, depending on the location of the primary site and the initial cancer stage. However, even in the general population (without genomic instability), radiation and chemotherapy are known to potentially induce numerous side effects and complications, including mucositis, dysphagia, taste changes, and fatigue. Other more severe complications, including osteonecrosis, fibrosis, and esophageal stenosis, exist as well but are relatively rare.
The management of FA patients with HNSCC is often difficult because of their sensitivity to both radiation therapy and chemotherapy agents (particularly cisplatin and mitomycin C).
1 Therefore, these therapeutic modalities are commonly avoided in the treatment plans for FA patients with HNSCC. Because of the complexity of treating FA patients with HNSCC, a comprehensive evaluation of these patients is very important. An understanding of how to manage these patients has not been previously well elucidated, secondary to the rare occurrence of FA in the general population and thus the small number of FA-associated neoplasms. Other studies evaluating neoplasms in patients with FA have been based on individual case reports or have been limited by small patient numbers, limited follow-up, and unconfirmed FA diagnoses. In this study, we reviewed the records of patients reported to the International Fanconi Anemia Registry (IFAR) for the occurrence of HNSCC over a 10-year period and defined its clinical course, management, and outcome. No other previously published study has comprehensively evaluated FA patients with HNSCCs over such a long follow-up period. The goal of this study is to help the treating physician care for FA patients with head and neck cancer.
MATERIALS AND METHODS

International Fanconi Anemia Registry
The IFAR was instituted in 1982 as a repository to collect clinical and genetic information from FA patients throughout the world. It currently has over 1,200 families enrolled. The registry collects longitudinal medical and other pertinent information from these patients by contacting them or surviving family members.
Patient Data Collection
Overall, we identified and collected information on 35 FA patients with HNSCC. We obtained patient or family consent when appropriate and obtained all available histories and medical, surgical, and radiation records from their respective treating hospitals. The diagnosis of FA was made by diepoxybutane breakage test, as previously described. 23 FA complementation groups were documented when possible. Human papilloma virus (HPV) status of the tumors were previously reported. 24 
Statistical Analysis
The end points of interest were overall, cause-specific, and disease-free survival times. Overall survival time was calculated as the time elapsed in months between the date of biopsy or surgery and the date of death or of last follow-up. Cause-specific survival time was calculated as the time elapsed in months between the date of biopsy or surgery and the date of death due to HNSCC or the last follow-up. Disease-free survival time was calculated as the time elapsed in months between the date of surgery and the date of disease recurrence. The Kaplan-Meier method was used to estimate the overall cause-specific and disease-free survival times. The log-rank test was used to detect any differences in HNSCC onset or survival between various patient subgroups.
RESULTS
Patient Demographic Information
Overall, we studied 22 female and 13 male FA patients who developed HNSCC (Table I) . Twenty-five patients were in complementation group FA-A; four in FA-C; and one each in FA-F, FA-J, FA-G, and FA-P. Two patients are currently untyped. The median age for development of HNSCC was 30 years; the mean was 32 years with a range from 14 to 48 years. In five patients (14%), the malignancy preceded the diagnosis of FA. Patients' records were screened for environmental risk factors known to enhance the risk of HNSCC: nine patients (26%) had a medical record indicating a history of tobacco use, alcohol consumption, or both (Table II) . Thirteen of the 35 patients (37%) had undergone previous HSCT.
Tumor Location and Staging
For patients who had tumors with a known clinical stage, eight patients were stage I, three were stage II, one was stage III, and 15 were stage IV. Of the 15 stage IV patients, 10 had N2b disease or greater. The TNM stages and tumor locations are summarized in Table II . The sites of cancers included the oral cavity (26 cases), larynx (6 cases), oropharynx (1 case), and the esophagus (1 case). One patient had an unknown primary. The most common subsite of oral cavity involvement was the tongue (n 5 14), followed by the alveolar ridge (n 5 4), the buccal mucosa (n 5 3), the retromolar trigone (n 5 2), and the floor of the mouth (n 5 2). The most common subsite of the larynx was the supraglottis (n 5 3).
Histological Characteristics
Surgical pathology reports or paraffin-embedded specimens were obtained from the treating institution and confirmed SCC in all patients. In 26 patients, information concerning tumor differentiation was available: nine were well differentiated, 13 were moderately differentiated, and four were poorly differentiated. The size of the primary tumor ranged from 0.4 to 5 cm (median 2.6 cm). The depth of invasion of the primary tumor ranged from 0.14 cm to 4.5 cm, with a median of 0.5 cm. Margin status was available for 24 patients: 18 patients had negative margins and six had microscopically positive margins, whereas two had close margins of less than 1 mm. Of 19 patients who underwent cervical lymph node dissection, 15 had positive lymph nodes. The average number of positive lymph nodes in the neck dissection specimens was three (range 1-10 nodes), with an average of 23 lymph nodes removed per patient. Extracapsular spread was identified in six of the patients' neck dissection specimens. HPV analysis of the primary tumor was conducted for 20 of the 35 patients in this study and published in a previous report. 24 Fifteen of the 20 patients (75%) had HPV positive primary tumors. All of the positive HPV tumors were typed as HPV-16. Thirteen of the HPV positive tumors were found in the oral cavity, whereas the remaining two tumors were found in the oropharyngeal region. There was no difference in survival outcomes for patients with HPV positive tumors compared to those with HPV negative tumors, although such a difference was perhaps undetected due to the limited number of HPV negative tumors.
Surgical Management and Complications
Thirty patients (86%) underwent surgical resection of their primary HNSCC, with 19 simultaneously undergoing a total of 21 neck dissections (8 modified radical neck dissections, 11 selective neck dissections, and 2 radical neck dissections). One patient died several days after a diagnostic biopsy, and a second patient had widely metastatic disease at presentation. One patient was diagnosed with an unknown primary and did not undergo a primary cancer resection. Of the 30 patients who underwent surgery, nine (29%) underwent flap reconstruction, including six free flap reconstruction (2 jejunal free flaps, 2 fibular free flaps, and 2 anterior lateral thigh free flaps), one regional flap reconstruction (gastric pull-up), and two local flap reconstructions (tongue flap and buccal fat pad). The remaining patients had primary closure of their defects. One patient had two sequential free flaps for a secondary primary tumor (an anterior lateral thigh free flap for reconstruction of the hypopharynx and a fibular free flap for reconstruction of the mandible). Seven patients had a total of nine postoperative complications, including two wound infections requiring hardware removal, one acute respiratory distress syndrome, one hematoma after fibular free flap reconstruction, two pharyngocutaneous fistulas, one marginal mandibular nerve weakness, one abdominal sepsis after total esophagectomy, and one aspiration pneumonia after supraglottic laryngectomy.
Patient Radiation Doses and Complications
Sixteen patients received radiation therapy: 13 patients underwent adjuvant postoperative radiation therapy; one patient received neoadjuvant radiation therapy; and two patients received palliative radiation therapy. Among these 16 patients who received radiation therapy, 69% (11 of 16) had stage IV cancers, 19% (3 of 16) had stage I tumors, and 6% (1 of 16) had stage III cancer. Tumor staging was unknown for one patient who received radiation (Table III) . The total radiation dose ranged from 2,500 cGy to 7,020 cGy, with a mean dose of 5,050 cGy. For patients from whom we were able to collect daily fraction data, doses ranged from 170 cGy to 200 cGy per treatment. Total length of treatment ranged from 31 days to 70 days.
The most prevalent complications during radiation treatment were high-grade mucositis (9 of 16), hematologic abnormalities (8 of 16), and dysphagia (8 of 16). Other complications included asystole/cardiac arrest, wound site breakdown, fibrosis, local edema, sepsis, tracheal stenosis, and radiation pneumonitis (Table III) . Eleven patients were able to complete the planned radiation dose, whereas for five patients (n 5 2 FANCA, 1 FANCC, 1 FANCJ), radiation therapy needed to be prematurely halted or interrupted due to toxicities associated with the treatment, primarily due to mucositis (Table III) . Patient complementation group or severity of FA phenotype (younger age at diagnosis of FA, history of HSCT, or younger age at diagnosis of SCC) did not correlate with poor tolerance of radiation, although it is possible that such associations could not be detected due to a relatively small sample size.
Chemotherapy and Complications
Three patients received conventional chemotherapy, whereas another three patients received targeted One patient who received conventional chemotherapy in addition to adjuvant radiation was not known to have FA until the development of treatment-related complications, including mucositis, persistent myelosuppression, hemorrhage, dysphagia, tracheal stenosis, and recurrent aspiration pneumonia. One patient received conventional chemotherapy without radiation for tumor recurrence, and treatment complications are unknown. Three patients received targeted chemotherapy with cetuximab (Erbitux; ImClone LLC), in addition to adjuvant or neoadjuvant radiation therapy. Among these three patients treated with cetuximab, only one patient was reported to have complications, which included pancytopenia, dysphagia, and folliculitis.
Second Primary Cancers
Patients with FA have a tendency to develop multiple malignancies. Overall, 12 (48%) of the 35 patients with HNSCC developed multiple malignancies, with five developing more than two primary malignancies. Of these patients, nine developed a second primary SCC, including anal SCC (n 5 2), cervical SCC (n 5 2), vulvar SCC (n 5 2), a second head and neck primary tumor (n 5 2), and cutaneous SCC (n 5 1). One patient developed a total of four malignancies (myelodysplastic syndrome, breast carcinoma, HNSCC, and anal SCC) before the age of 40 years and was not diagnosed as having FA until after the third malignancy, when the patient was found to have anemia during preoperative workup.
Survival Outcomes
Follow-up and outcome information was available for all 35 patients. Thirty patients (86%) died during the study period. Sixteen patients (64%) died as a consequence of HNSCC. Overall survival time ranged from less than 1 month to greater than 410 months (34 years). The median follow-up, based on the five patients who were alive at last follow-up, was 178 months (14 years). Seventeen (49%) of the patients had recurrence of their tumor, with a median disease-free interval of 22 months. Among all patients with stage I cancers, 88% (7 of 8) experienced tumor recurrence-and 100% (3 of 3) of stage II cancers, 0% (0 of 1) of stage III cancers, and 27% (4 of 15) of stage IV cancers recurred. Eight patients were known to have had a local recurrence and three had a neck recurrence, whereas six patients developed recurrence both locally and regionally. Four patients progressed to have distant metastases. Twelve of the patients who experienced tumor recurrence underwent surgical resection. Of these 12 patients, two patients received adjuvant chemoradiation; two patients were treated with adjuvant chemotherapy; and one patient received postoperative radiation alone. One patient received radiation therapy without surgical resection for tumor recurrence. Of the 11 patients with early stage cancers at initial presentation (stage I and II), six patients died of recurrent locoregional disease. Of the 16 patients who underwent radiation therapy, 15 patients died-with four patients dying from complications while receiving radiation therapy (3 from sepsis; 1 from cardiac arrest). The 2-year cause-specific, disease-free, and overall survival rates, based on Kaplan-Meier survival estimates, were 79%, 75%, and 71%, respectively. The 5-year cause-specific, disease-free, and overall survival rates, based on Kaplan-Meier survival estimates, were 47%, 43%, and 39%, respectively (Fig. 1) . HPV status, complementation group, history of radiation therapy or chemotherapy, and site of primary tumor did not significantly affect HNSCC onset or survival in this cohort.
DISCUSSION
The propensity for patients with FA to develop cancer is well documented. Kaplan et al. 25 suggest that there are two major defects that play a role in the development of malignancies in patients with FA: defective chromosomal stability and immunodeficiency. Chromosomal studies 26 in patients with FA have shown an increased spontaneous instability. Aberrations, such as breaks, fragments, radials, and dicentric chromosomes, have been described. The best-described malignancies associated with FA are hematologic in origin. 27 Previous reports also suggest that patients with FA are predisposed to solid tumors, particularly HNSCC and SCC of the anogenital region. Lustig et al. 28 reviewed the literature and identified 17 cases of HNSCC associated with FA. In their report, they concluded that these carcinomas occurred in young patients (< 30 years); were equally common in females as in males; and originated from the tongue (n 5 9), gingiva (n 5 3), pyriform sinus (n 5 1), postcricoid region (n 5 1), and upper third of the esophagus (n 5 1). Another previous study by Kutler et al. 15 of 754 subjects with FA determined that the cumulative incidence of developing a solid tumor approaches 28%; the cumulative incidence of developing HNSCC is 14% by 40 years of age. 18 Not only are patients with FA strongly predisposed to develop HNSCC, but they also have an earlier onset of HNSCC. Patients with phenotypically mild FA who do not develop bone marrow failure or leukemia and who survive into the third decade of life are at a significant risk of developing HNSCC. In addition, as the life expectancies of more severely affected patients with FA increase with improvements in HSCT, the number of patients developing HNSCC will most likely increase as well. A history of HSCT is thought to increase FA patients' risk of developing subsequent solid malignancies, particularly HNSCC. 29, 30 In one study by Rosenberg et al., 22 the age-specific hazard of SCC was 4.4-fold higher in patients who received HSCTs than in those who did not (P 5 .003), and SCCs occurred at significantly younger ages in the former (respective medians, 18 vs. 33 years, P 5 .004). In this cohort, 13 of the 35 patients (37%) had a previous history of HSCT prior to developing HNSCC.
In this study, FA patients developed HNSCC at a very young age compared to the general population, with a mean of 32 years in our population versus 63 years as reported in a general population. 31 In addition, HNSCC developed often without a history of tobacco use or alcohol consumption, which are common risk factors for HNSCC in the general population (26% in our FA population vs. 75%-85% in a general HNSCC population 31 ). However, even a very small amount of alcohol consumption, which perhaps would not be reported by patients, may be quite carcinogenic in this patient population. [32] [33] [34] Based on reports in the literature that document development of HNSCC at ages as young as 13 (average 28) in FA patients, 29 increased screening and awareness of HNSCC should be maintained in this population starting at a young age. Based on the age distribution in this study, screening of the oral cavity and oropharynx should start prior to 15 years of age. This would include a detailed evaluation and physical examination of the FA patient every 3 to 4 months by an expert in head and neck diseases. In addition, fiberoptic evaluation of the larynx and hypopharynx should also be done in order to find early cancers of the larynx and pharynx. However, in patients with FA with a history of precancerous leukoplakia or recurrent oral lesions, head and neck examinations are recommended every 6 to 8 weeks. Early identification of HNSCC, and thus early therapeutic interventions, may translate into improved survival, or at least may reduce the necessity for more aggressive surgical approaches. Conversely, patients who develop HNSCC at young ages may be appropriate candidates to screen for FA.
Head and neck squamous cell carcinomas in FA patients were most commonly located in the oral cavity (26 of 35, 74%), particularly in the tongue (14 of 35, 40%). This finding is similar to the findings in the review by Lustig et al., 28 who found a 52% incidence of tongue carcinoma. The affinity of FA-associated SCC to the oral cavity, and especially to the tongue, is striking because the incidence of tongue carcinoma in the general population is only 10% to 20%. 35, 36 The development of multiple primary malignancies, particularly SCC, is another common finding in patients with FA. The reason for the strong propensity for patients with FA to develop multiple oral cavity SCCs and secondary SCCs of the mucous membranes is unclear. Kennedy and Hart 37 noted that patients with FA have a marked predisposition for carcinomas of the mucous membranes of the anogenital and oral areas. In their review, 37 they found that five (36%) of 14 patients developed carcinoma in more than one mucosal site.
A hypothesis for predisposition to multiple SCCs is the possible increased susceptibility of the oral cavity and genital region to local predisposing factors, including viruses. The virus association is interesting because the mucous membranes are a common route for oncogenic viral infections, especially HPV. The immunosuppression associated with persistent bone marrow failure and the underlying genetic instability in these patients may predispose these patients to viral infections. In addition, studies have demonstrated an interaction between the HPV16 E7 oncoprotein and the FA pathway. [38] [39] [40] It has also been hypothesized that the FA pathway contributes to the repair of DNA damage induced by HPV16 E7, providing one explanation for why FA patients are predisposed to HPV-associated HNSCCs. 41 In FA patients from North America, a high percentage (84%) of HNSCCs were found to be positive for highrisk HPV DNA. Consistent with the role of HPV in these cancers, mutations in p53-a tumor suppressor that is inactivated by HPV 16 E6-were not found in HNSCCs from these patients. 24 However, in patients from European countries, HNSCCs were negative for HPV DNA, and more than 50% of these tumors had p53 mutations. 42 Based on this conflicting data, it remains unclear whether HPVs play a role in HNSCCs arising in FA patients. In this study, which is based on previously published data, 24 15 of the 20 HNSCCs (75%) that were tested for HPV were positive. In addition, the oncogenic HPV-16 was identified in all positive samples. Interestingly, 13 of the HPV positive tumors were found in the oral cavity, whereas the remaining two tumors were found in the oropharyngeal region. This is inconsistent with the literature from the general population, where HPV positivity is related to the oropharyngeal region rather than the oral cavity. 43, 44 The reason for this difference is not known at this point. Because of the possible high rate of HPV-positivity in FA-associated HNSCC, as well as the propensity for them to develop anogenital cancers, both male and female FA patients should be considered candidates for the HPV vaccine.
The main treatment modality for FA patients with HNSCC is surgery because of the potential risks that are associated with primary radiation therapy and chemotherapy. The main preoperative problem in patients with FA is the bone marrow failure that is associated with this disorder, requiring preoperative consultation with a hematologist and the possibility of blood and platelet transfusion before surgery. A hematologist should also be available postoperatively to help manage any complicating hematologic abnormalities. However, no patient in this study had severe bone marrow failure during postoperative hospitalization.
This study shows that FA patients can tolerate large complex surgeries with free flap reconstructions without significant morbidity or mortality. Indeed, one patient underwent two separate free flap reconstructions without experiencing life-threatening complications. 45 However, the patient did develop a pharyngocutaneous fistula during the postoperative period of the second surgery, which resolved with local wound care. Other postoperative complications included wound infections, hematomas, pharyngocutaneous fistulas, and aspiration pneumonia, which are not very different than the complications in the general population. In this study of FA-associated HNSCC, there were postoperative complications in seven of 30 patients (23%) who underwent surgical resections; however, most patients tolerated surgery well, with minimal long-term morbidity.
In a literature review by Lustig et al., 28 the authors concluded that in the five patients who were treated for HNSCC by radiation therapy as primary or adjuvant treatment, all of them tolerated it without difficulty. In contrast, postoperative radiation therapy was used in 16 patients in this study with mixed success. Patients suffered complications even at low doses of radiation; no minimal safe dose of radiation was seen in this cohort because complications arose in one patient at 2,500 cGy. Compared to a target minimum dose of 5,760 cGy for postoperative patients in the general population, 46 FA patients in this cohort received a mean dose of 5,050 cGy. This decreased average dose was due to the intolerance of these FA patients to the toxicity of the treatment, requiring termination or interruption of therapy in five patients. Because FA patient tumors carry FA mutations, the tumors themselves may be more sensitive to radiation, and consideration of lower doses of radiation to achieve cure in FA patients may be appropriate.
Radiation treatment for head and neck cancers is associated with numerous complications in the general population, with the most common being high-grade mucositis, dysphagia, dry mouth, and taste changes. High-grade mucositis is reported to range from 34% to 57% in the general population. 47 Mucositis was seen in nine of 16 (56%) patients in our cohort, suggesting that it poses a significant risk in FA patients. In addition, pancytopenia, which is a rare complication in the general population, was experienced at high rates (8 of 16) in this cohort of FA patients. The pancytopenia is of particular concern in dealing with postradiation complications in these patients because it can lead to bleeding complications, fatigue, poor wound healing, and infection. Due to the underlying stem-cell problems in these patients, the time to recovery of normal blood counts may also be delayed. In this cohort, two patients developed sepsis, one had recurrent pneumonia, and two had bleeding complications. Based on this case series, it is clear that FA patients should not be precluded from receiving postoperative radiation therapy. However, it is important to be aware of complications that may present in FA patients, particularly hematologic abnormalities and high-grade mucositis. Therefore, we recommend frequent monitoring of hematologic counts throughout radiation therapy. In particular, careful monitoring of white blood cell counts is needed to avoid potential infections and sepsis. Close monitoring of mucositis should be performed, especially because severe mucositis can limit the completion of radiation therapy. For patients with significant complications, temporarily suspending therapy may be needed to avoid worsening of the complications and allow for recovery. In developing radiation treatment plans, longer courses at lower daily doses may be considered in order to decrease risk of developing significant toxicities. The addition of chemotherapy to radiation in three patients in this cohort resulted in significant complications (including interruption or cessation of therapy in 2), suggesting the need for special care when considering chemotherapy in addition to radiation in FA patients. Three patients received targeted chemotherapy with cetuximab (Erbitux, ImClone LLC), which they tolerated well, but all three died of recurrent or metastatic disease.
The 5-year cause-specific and overall survival was poor in this patient population (47% and 39%, respectively), with a median overall survival length of 42 months. Five-year disease-free survival was also poor (43%), with a median disease-free interval of 22 months. Compared with other studies evaluating outcomes for patients with oral cavity SCC younger than 35 years, the outcome for those with FA-associated HNSCC is significantly worse. In a previous study of patients younger than 35 years with oral cavity carcinoma, the 5-year survival was 57.3%. 48 Another study 49 analyzing 12 patients younger than 35 years showed a 2-year survival of 57%. The underlying genomic instability in patients with FA may increase the likelihood of developing genomic alterations that select for a more aggressive phenotype or allow for the development of an early recurrence. Therefore, aggressive therapy should be considered in all FA patients, with a balance between appropriately aggressive oncologic surgery and postoperative radiation. Special considerations with regard to blood counts, infections, and side-effects should be a part of the normal posttherapy evaluation of FA patients. Advancements in targeted therapies such as cetuximab (Erbitux, ImClone LLC), may also improve the treatment of these patients, but more studies concerning the efficacy in these patient are needed.
Although the large number of patients and the long 10-year follow-up make the IFAR database unique, there are potential limitations. One problem is the possibility of selective reporting. Another is that there was no prospectively defined study design; reporting of malignancy development was determined by the participating physicians even after the subjects were entered into the registry. A third consideration is the completeness and accuracy of data reporting; no audits of reporting centers were performed. However, by using this registry, we have been able to evaluate HNSCC in this rare population of patients with a known genetic disease characterized by chromosomal instability.
CONCLUSION
To our knowledge, this registry-based study represents the largest reported series of HNSCCs associated with FA. Patients with FA have an increased incidence of aggressive HNSCC that frequently develops at an early age and has a very poor prognosis. Primary surgery remains the mainstay for treatment; radiation therapy has been used in high-stage cancers, but its success has been limited by severe mucositis and pancytopenia. Careful screening of the head and neck in patients with FA is essential to discover lesions at an early stage. There is also a tendency for the development of multiple SCCs of the mucous membranes of the aerodigestive and anogenital tracts in the setting of FA. Further studies of FA patients' responses to various treatment modalities should be conducted to establish appropriate therapeutic guidelines in order to achieve favorable oncologic outcomes while limiting toxicity. Additionally, the strong association between FA and SCC makes FA an excellent framework to study the role of chromosomal instability in the initiation and progression of SCC in all patients.
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